Advertisement

Drugs

, Volume 50, Issue 2, pp 250–262 | Cite as

Guidelines for the Use of Propafenone in Treating Supraventricular Arrhythmias

  • A. G. Ravi Kishore
  • A. John Camm
Practical Therapeutics

Summary

Propafenone is a sodium channel blocking agent with a mild β- and calcium channel-blocking activity. Several controlled and noncomparative studies have documented its efficacy in a variety of supraventricular arrhythmias in both adults and children.

Propafenone is comparable with other Vaughan-William class I antiarrhythmic drugs for acute conversion of atrial fibrillation. It is also comparable with other drugs for prevention of recurrences in paroxysmal atrial fibrillation and for maintenance of sinus rhythm following successful cardioversion of chronic atrial fibrillation.

Although propafenone is effective in the acute management of junctional reentrant tachycardias, the availability of safer drugs precludes its routine use for these arrhythmias. It may, however, be preferred for the acute management of haemodynamically well tolerated pre-excited atrial fibrillation in patients with the Wolff-Parkinson-White (WPW) syndrome. It also has documented efficacy in the long term therapy of patients with junctional tachycardias, and is a useful first-line drug in the management of arrhythmias in patients with the WPW syndrome, particularly when there is a short anterograde refractory period of the accessory pathway.

Noncomparative studies have confirmed good efficacy and tolerability of propafenone in the short and long term management of paediatric supraventricular arrhythmias. It seems to be particularly effective for the treatment of ectopic atrial and junctional tachycardias, which are generally difficult arrhythmias to manage.

Propafenone appears to have an acceptable adverse effect profile during both short and long term therapy. As with most other antiarrhythmic agents, there is a proarrhythmic potential. This has also been observed in children. There is a theoretical possibility that the β-blocking properties of propafenone may protect against its proarrhythmic potential. However, this has not been confirmed in clinical studies.

In conclusion, propafenone appears to be effective in the management of a wide spectrum of supraventricular arrhythmias. It should be considered among the first line drugs for management of these arrhythmias in patients without structural heart disease.

Keywords

Atrial Fibrillation Flecainide Atrial Flutter Propafenone Paroxysmal Atrial Fibrillation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Furlanello F, Guarnerio M, Inama G, et al. Long term follow up of patients with inducible supraventricular tachycardia treated with flecainide or propafenone: therapy guided by transoesophageal electro-pharmacologic testing. Am J Cardiol 1992; 70: 19A–25APubMedCrossRefGoogle Scholar
  2. 2.
    Inama G, Furlanello F, Vergara G, et al. Electro-pharmacological test with drugs of 1C class in PSRT: can the negative result of one drug be predictive of the ineffectiveness of other drugs of the same class? Flecainide vs propafenone. N Trends Arrhythmias 1990; 6: 409–18Google Scholar
  3. 3.
    Malfatto G, Pessano P, Zaza A, et al. Experimental evidence for beta-adrenergic blocking properties of propafenone and for their potential clinical relevance. Eur Heart J 1993; 14: 1253–7PubMedCrossRefGoogle Scholar
  4. 4.
    Myerburg RJ, Kessler KM, Cox MM, et al. Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propronalol. Circulation 1989; 80: 1571–9PubMedCrossRefGoogle Scholar
  5. 5.
    Bryson HM, Palmer KJ, Langtry HD, et al. Propafenone: a reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias. Drugs 1993; 45: 85–130PubMedCrossRefGoogle Scholar
  6. 6.
    Vita JA, Freidman PL, Cantillon C, et al. Efficacy of intravenous propafenone for the acute management of atrial fibrillation. Am J Cardiol 1989; 63: 1275–8PubMedCrossRefGoogle Scholar
  7. 7.
    Bellandi F, Cantini F, Pedone T, et al. The efficacy of intravenous propafenone and amiodarone in the conversion of recent onset atrial fibrillation: a 1 year follow-up with oral treatment. G Ital Cardiol 1993; 23: 261–71PubMedGoogle Scholar
  8. 8.
    Negrini M, Gibelli G, De Ponti C. Propafenone compared with amiodarone for conversion of paroxysmal atrial fibrillation to sinus rhythm [abstract]. J Am Coll Cardiol 1991; 17: 131ACrossRefGoogle Scholar
  9. 9.
    Bertini G, Conti A, Fradella G, et al. Propafenone versus amiodarone in field treatment of primary atrial tachyarrhythmias. J Emerg Med 1990; 8: 15–20PubMedCrossRefGoogle Scholar
  10. 10.
    Proclemer A, Miorelli M, Pavan A, et al. Intravenous propafenone in paroxysmal atrial fibrillation: a randomised, placebo controlled, double-blind, multi-centre clinical trial [abstract]. J Am Coll Cardiol 1994; Special Issue (Feb): 368AGoogle Scholar
  11. 11.
    Kingma JH, Suttorp MJ. Acute pharmacologic conversion of atrial fibrillation ad flutter: the role of flecainide, propafenone and verapamil. Am J Cardiol 1992; 70: 56A–61APubMedCrossRefGoogle Scholar
  12. 12.
    Capucci A, Rubino I, Boriani G, et al. A placebo controlled study comparing oral propafenone to quinidine plus digoxin in conversion of recent onset atrial fibrillation [abstract]. Eur Heart J 1991; 12 Suppl.: 338Google Scholar
  13. 13.
    Capucci A, Boriani G, Botto GL, et al. Conversion of recent onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol 1994; 74: 503–5PubMedCrossRefGoogle Scholar
  14. 14.
    Capucci A, Lenzi T, Boriani G, et al. Efficacy of propafenone to convert atrial fibrillation to sinus rhythm: a controlled study comparing acute intravenous infusion versus oral loading [abstract]. Circulation 1993; 88: 1–445Google Scholar
  15. 15.
    Berti S, Trianni G, Cataldo P, et al. Low dose propafenone versus deslanoside for the out-of-hospital treatment of paroxysmal atrial fibrillation: a single blind study [abstract]. PACE 1994; 17: 764Google Scholar
  16. 16.
    Bianconi L, Boccadamo R, Pappalardo A, et al. Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol 1989; 64: 335–8PubMedCrossRefGoogle Scholar
  17. 17.
    Gentili C, Giordano F, Alois A, et al. Efficacy of intravenous propafenone in acute atrial fibrillation complicating open-heart surgery. Am Heart J 1992; 123: 1225–8PubMedCrossRefGoogle Scholar
  18. 18.
    Goy JJ, Metrailler JC, Humair L, et al. Restoration of sinus rhythm in atrial fibrillation of recent onset using intravenous propafenone. Am Heart J 1991; 122: 1788–90PubMedCrossRefGoogle Scholar
  19. 19.
    Capucci A, Boriani G. Intravenous administration of propafenone [letter]. J Am Coll Cardiol 1992; 19: 1368–9PubMedCrossRefGoogle Scholar
  20. 20.
    Gillis AM, Kates RE. Myocardial uptake kinetics and pharmacodynamics of propafenone in the isolated perfused rabbit heart. J Pharmacol Exp Ther 1986; 237: 708–12PubMedGoogle Scholar
  21. 21.
    Margheri M, Fradella G, Maioli M, et al. Efficacy of intravenous and per oral propafenone in the ambulatory treatment of recent onset atrial fibrillation. G Ital Cardiol 1992; 22: 257–65PubMedGoogle Scholar
  22. 22.
    Suttorp MJ, Kingma HJ, Jessuran ER, et al. The value of Class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990; 16: 1722–7PubMedCrossRefGoogle Scholar
  23. 23.
    Cointe R, Metge M, Bru P, et al. Intravenous and oral propafenone in the treatment and prevention of paroxysmal atrial fibrillation. Ann Cardiol Angiol Paris 1993; 42: 223–7Google Scholar
  24. 24.
    Waldo AL, McLean WAH, Cooper TR, et al. The use of temporarily placed epicardial wire electrodes for the diagnosis and treatment of cardiac arrhythmias following open-heart surgery. J Thorac Cardiovasc Surg 1978; 76: 500–5PubMedGoogle Scholar
  25. 25.
    Gavaghan TP, Campbell TJ, Fenely MP, et al. Atrial tachyarrhythmias after cardiac surgery: results of disopyramide therapy. Aust NZ J Med 1985; 15: 27–32CrossRefGoogle Scholar
  26. 26.
    Campbell TJ, Gavaghan TP, Morgan JJ. Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass: comparison with disopyramide and digoxin in a randomised trial. Br Heart J 1985; 54: 86–90PubMedCrossRefGoogle Scholar
  27. 27.
    Installe E, Schoevaerdts JC, Gadisseux P, et al. Intravenous amiodarone in the treatment of various arrhythmias following cardiac operations. J Thorac Cardiovasc Surg 1981; 81: 302–8PubMedGoogle Scholar
  28. 28.
    Weiner P, Bassan MM, Jarchowsky J, et al. Clinical course of acute atrial fibrillation treated with rapid digitalisation. Am Heart J 1983; 105: 223–7PubMedCrossRefGoogle Scholar
  29. 29.
    Wafa SS, Ward DE, Parker J, et al. Efficacy of flecainide acetate for atrial arrhythmias following coronary artery bypass grafting. Am J Cardiol 1989; 63: 1058–64PubMedCrossRefGoogle Scholar
  30. 30.
    Connolly SJ, Mulji AS, Hoffert DL, et al. Randomised placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery. J Am Coll Cardiol 1987; 10: 1145–8PubMedCrossRefGoogle Scholar
  31. 31.
    Tisi G, Annoni P, Baroffio R, Cazzaniga L, et al. Emergency treatment of supraventricular tachyarrhythmias. Efficacy and safety of intravenous propafenone. Cardiologia 1992; 37: 621–5PubMedGoogle Scholar
  32. 32.
    Grey E, Silverman D. Efficacy of type 1C antiarrhythmic agents for treatment of resistant atrial fibrillation. PACE 1993; 16, 2235–40PubMedCrossRefGoogle Scholar
  33. 33.
    Antmann EM, Beamer AD, Cantillon C, et al. Long term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and flutter. J Am Coll Cardiol 1988; 12: 1005–11CrossRefGoogle Scholar
  34. 34.
    Cobbe SM. A randomised placebo controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachyarrhythmias [abstract]. J Am Coll Cardiol 1994; Special Issue (Feb): 251AGoogle Scholar
  35. 35.
    Cobbe SM. Drug therapy of supraventricular tachyarrhythmias — based on efficacy or futility? Eur Heart J 1994; 15 Suppl. A: 22–6PubMedGoogle Scholar
  36. 36.
    Coumel P, Leclercq JF, Assayag P. European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. Am J Cardiol 1984; 54: 60D–66DPubMedCrossRefGoogle Scholar
  37. 37.
    Reimold SC, Cantillon CO, Freidman PL, et al. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993; 71: 558–63PubMedCrossRefGoogle Scholar
  38. 38.
    Tarquinii M, Lolli C, Foscoli M, et al. Prevention of atrial fibrillation with propafenone after withdrawal of amiodarone because of side effects. Clin Ter 1993; 142: 341–6PubMedGoogle Scholar
  39. 39.
    Richiardi E, Gaita F, Greco C, et al. Propafenone versus hydroquinidine in long term pharmacological prophylaxis of atrial fibrillation. Cardiologia 1992; 37: 123–7PubMedGoogle Scholar
  40. 40.
    Chimienti M, Casadei G. Flecainide versus propafenone in the prevention of paroxysmal atrial fibrillation: a long term randomised multi-centre study [abstract]. J Am Coll Cardiol 1994; Special Issue (Feb): 91AGoogle Scholar
  41. 41.
    Chimienti M, Casadei G. Tolerance and efficacy of flecainide versus propafenone for the long term management of paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia [abstract]. Circulation 1993; 88: 1–446Google Scholar
  42. 42.
    Bianconi L, Mennuni M, Castro A, et al. Pre-treatment with oral propafenone in electrical cardioversion of chronic atrial fibrillation [abstract]. PACE 1994; 17: 831Google Scholar
  43. 43.
    Mannino MM, Mehta D, Gomes JA. Current treatment options for paroxysmal supraventricular tachycardia. Am Heart J 1994; 127: 475–80PubMedCrossRefGoogle Scholar
  44. 44.
    Santinelli V, de Paola M, Turco P, et al. Paroxysmal supraventricular tachycardia: experience with propafenone. Angiology 1989; 40; 563–8PubMedCrossRefGoogle Scholar
  45. 45.
    Boahene KA, Klein GJ, Yee R, et al. Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length. J Am Coll Cardiol 1990; 16: 1408–14PubMedCrossRefGoogle Scholar
  46. 46.
    Camm AJ, Katrisis D, Nunain SO. Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome. Am J Cardiol 1992; 70: 33A–37APubMedCrossRefGoogle Scholar
  47. 47.
    Breithardt G, Borggrefe M, Weibringhaus E, et al. Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiologic findings and long term follow up. Am J Cardiol 1984; 54: 29D–39DPubMedCrossRefGoogle Scholar
  48. 48.
    Dubuc M, Kus T, Campa MA, et al. Electrophysiologic effects of intravenous propafenone in Wolff Parkinson White syndrome. Am Heart J 1989; 117: 370–6PubMedCrossRefGoogle Scholar
  49. 49.
    Auricchio A. Reversible protective effect of propafenone or flecainide during atrial fibrillation in patients with an accessory atrio-ventricular connection. Am Heart J 1992; 124: 932–7PubMedCrossRefGoogle Scholar
  50. 50.
    Pritchett EL, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic PSVT: a randomised placebo controlled trial in patients tolerating oral therapy. Ann Intern Med 1991; 114; 539–44PubMedGoogle Scholar
  51. 51.
    Chimienti M, Casadei G. Flecainide versus propafenone in the long term prevention of paroxysmal supraventricular tachycardia: a multi-centre study [abstract]. PACE 1994; 17: 763CrossRefGoogle Scholar
  52. 52.
    Vassiliadis I, Papoutsakis P, Kallikazaros I, et al. Propafenone in the prevention of non-ventricular arrhythmias associated with the WPW syndrome. Int J Cardiol 1990; 27: 63–70PubMedCrossRefGoogle Scholar
  53. 53.
    Gaita F, Giustetto C, Riccardi R, et al. Wolff-Parkinson-White syndrome: identification and management. Drugs 1992; 43: 185–200PubMedCrossRefGoogle Scholar
  54. 54.
    Ganz LI, Freidman PL. Supraventricular tachycardia. N Engl J Med; 332: 162-73Google Scholar
  55. 55.
    Vignati G, Mauri L, Figini A. The use of propafenone in the treatment of tachyarrhythmias in children. Eur Heart J 1993; 14: 546–50PubMedCrossRefGoogle Scholar
  56. 56.
    Musto B, D’Onofrio A, Cavallaro C, et al. Electrophysiological effects and clinical efficacy of propafenone in children with recurrent paroxysmal supraventricular tachycardia. Circulation 1988; 78: 863–9PubMedCrossRefGoogle Scholar
  57. 57.
    Reimer A, Paul T, Kallfelz HC. Efficacy and safety of intravenous and oral propafenone in paediatric cardiac dysrhythmias. Am J Cardiol 1991; 68: 741–4PubMedCrossRefGoogle Scholar
  58. 58.
    Garson Jr A, Moak JP, Smith Jr RT, et al. Usefulness of intravenous propafenone for control of postoperative junctional ectopic tachycardia. Am J Cardiol 1987; 59; 1422–4PubMedCrossRefGoogle Scholar
  59. 59.
    Guccione P, Drago F, Di Donato R, et al. Oral propafenone therapy for children with arrhythmias: efficacy and adverse effects in midterm follow-up. Am Heart J 1991; 122: 1022–7PubMedCrossRefGoogle Scholar
  60. 60.
    Beaufort-Krol GC, Bink-Boelkens MT. Oral propafenone as treatment for incessant supraventricular and ventricular tachycardia in children. Am J Cardiol 1993; 72: 1213–4PubMedCrossRefGoogle Scholar
  61. 61.
    Janousek J, Paul T, Reimer A, et al. Usefulness of propafenone for supraventricular arrhythmias in infants and children. Am J Cardiol 1993; 72: 294–300PubMedCrossRefGoogle Scholar
  62. 62.
    Paul T, Reimer A, Janousek J, et al. Efficacy and safety of propafenone in congenital junctional ectopic tachycardia. J Am Coll Cardiol 1992; 20: 911–4PubMedCrossRefGoogle Scholar
  63. 63.
    Weber H, Eigster G, Wesselhoeft H. Experience with propafenone in the treatment of arrhythmias in paediatric patients. In: Schlepper M, Olson B, editors. Cardiac arrhythmias: proceedings of the First International Rhytmonorm Congress. New York: Springer Verlag, 1983: 185–90Google Scholar
  64. 64.
    Lucet V, Do Ngoc D, Fidelle J, et al. Antiarrhythmic efficacy of propafenone in children. Apropos of 30 cases. Arch Mal Coeur Vaiss 1987; 80: 1385–93PubMedGoogle Scholar
  65. 65.
    Liguori A, di Ieso N, D’Armiento FP, et al. Intravenous propafenone for suppression of symptomatic atrial fibrillation and atrial flutter in a first aid hospital. Riv Eur Sci Med Farmacol 1992; 14: 229–32PubMedGoogle Scholar
  66. 66.
    Marcus FL. The hazards of using type 1C antiarrhythmic drugs for the treatment of atrial fibrillation. Am J Cardiol 1990: 66; 366–7PubMedCrossRefGoogle Scholar
  67. 67.
    Hernandez M, Reder RF, Marinchak RA, et al. Propafenone for malignant ventricular arrhythmia: an analysis of the literature. Am Heart J 1991; 121 (4): 1178–84PubMedCrossRefGoogle Scholar
  68. 68.
    Ravid S, Podrid PJ, Novrit B. Safety of long term propafenone therapy for cardiac arrhythmia-experience with 774 patients. J Electrophysiol 1987; 1: 580–90CrossRefGoogle Scholar
  69. 69.
    Ravid S, Podrid PJ, Lampert S, et al. Congestive heart failure induced by six of the newer antiarrhythmic drugs. J Am Coll Cardiol 1989; 14: 1326–30PubMedCrossRefGoogle Scholar
  70. 70.
    Pritchett EL, Wilkinson WE, Clair WK, et al. Comparison of mortality in patients treated with propafenone to those treated with a variety of antiarrhythmic drugs for supraventricular arrhythmias. Am J Cardiol 1993; 72: 108–10PubMedCrossRefGoogle Scholar
  71. 71.
    Kugler JD, Danford DA, Deal BJ, et al. Radiofrequency catheter ablation in children and adolescents. N Engl J Med 1994; 330: 1481–7PubMedCrossRefGoogle Scholar
  72. 72.
    Saul JP, Hulse JE, Walsh EP. Late enlargement of radiofrequency lesions in infant lambs: implications for ablation procedures in small children. Circulation 1994; 90: 492–9PubMedCrossRefGoogle Scholar
  73. 73.
    Kugler JD. Radiofrequency catheter ablation for supraventricular tachycardia: should it be used in infants and small children? Circulation 1994; 90: 639–41PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • A. G. Ravi Kishore
    • 1
  • A. John Camm
    • 1
    • 2
  1. 1.Department of Cardiological SciencesSt George’s Hospital Medical SchoolLondonEngland
  2. 2.St George’s Hospital Medical SchoolLondonEngland

Personalised recommendations